- Home
- MVF vs AMRN Comparison
MVF vs AMRN Comparison
Compare MVF & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$16.54
Company Overview
Basic Information| Metric | MVF | AMRN |
|---|---|---|
| Founded | 1988 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.0M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | MVF | AMRN |
|---|---|---|
| Price | $6.97 | $16.54 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 162.8K | 76.2K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.85 | $7.08 |
| 52 Week High | $7.19 | $20.90 |
Technical Indicators
Market Signals| Indicator | MVF | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 50.81 |
| Support Level | $6.83 | $15.36 |
| Resistance Level | $6.94 | $16.25 |
| Average True Range (ATR) | 0.06 | 0.67 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 94.11 | 60.32 |
Price Performance
Historical Comparison MVF
AMRN
About MVF Blackrock MuniVest Fund Inc.
Blackrock Munivest Fund Inc is an investment management firm. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The company invests in various sectors such as Health; Transportation; Utilities; Education; Tobacco; Housing and others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.